Indivior PLC $INDV is Two Seas Capital LP’s 3rd Largest Position

Two Seas Capital LP cut its stake in shares of Indivior PLC (NASDAQ:INDV) by 51.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 5,109,198 shares of the company’s stock after selling 5,394,954 shares during the quarter. Indivior makes up 3.8% of Two Seas Capital LP’s holdings, making the stock its 3rd biggest holding. Two Seas Capital LP’s holdings in Indivior were worth $183,318,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. WINTON GROUP Ltd purchased a new stake in shares of Indivior during the 4th quarter valued at $291,000. Vise Technologies Inc. purchased a new stake in shares of Indivior during the 4th quarter valued at $256,000. Bank of New York Mellon Corp grew its stake in shares of Indivior by 100.4% during the 4th quarter. Bank of New York Mellon Corp now owns 700,272 shares of the company’s stock valued at $25,126,000 after buying an additional 350,839 shares during the period. Natixis Advisors LLC purchased a new stake in shares of Indivior during the 4th quarter valued at $376,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Indivior during the 4th quarter valued at $1,109,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Trading Up 0.5%

NASDAQ:INDV opened at $37.62 on Friday. The firm has a market capitalization of $4.59 billion, a price-to-earnings ratio of 19.29 and a beta of 0.88. The firm’s fifty day simple moving average is $34.61 and its 200 day simple moving average is $34.10. Indivior PLC has a twelve month low of $13.42 and a twelve month high of $41.00.

Indivior (NASDAQ:INDV) last posted its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. The business had revenue of $317.00 million for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. On average, analysts predict that Indivior PLC will post 4.05 earnings per share for the current year.

Wall Street Analyst Weigh In

INDV has been the topic of several recent research reports. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Indivior currently has a consensus rating of “Buy” and an average price target of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.